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Abstract 
The project was conducted with the purpose of producing a pamphlet, in conjunction with 
Sydänlapset ja -aikuiset ry, for public education in Long QT syndrome (LQTS). This was 
undertaken in the hope of, as previously mentioned, informing the public of LQTS and thereby 
decreasing the risk of sudden cardiac death in regards to LQTS. In the thesis information was 
gathered dealing with LQTS in addition to information on proper pamphlet compilation. Whereby 
the information was condensed and used to produce the pamphlet. The pamphlet was then 
given to Sydänlapset ja -aikuiset ry in electronic form to be placed on the world wide web for 
members of the public to print and use as needed. 
 
The theoretical background was based on information gathered from various research papers 
regarding LQTS and pamphlet production. Information was also gathered from various 
foundations such as the Sudden Arrhythmic Death Foundation (SADS). Upon completion of the 
theoretical portion, a pamphlet was produced containing basic information regarding LQTS. In 
order to check the pamphlet for readability, educational contents and overall attractiveness the 
pamphlet was presented to nursing staff of Jyväskylä Central Hospital whereby feedback was 
attained in the form of a questionnaire.  Additionally the pamphlet was also shown to various 
members of the public to confirm that the language and terms used in the pamphlet were simple 
and easy to understand. Thus, the information compiled included a description of LQTS, 
information regarding the compilation of educational material for public dissemination and lastly 
feedback received from nursing staff regarding the pamphlet and its educational value.  
 
Overall, the feedback received was positive; fifteen nurses from Jyväskylä Central Hospital 
paediatric ward participated in the pamphlet’s evaluation. Feedback was gathered with the aid of 
a 13 point questionnaire. Various recommendations were made by the participants and taken 
into consideration by the authors. Necessary changes were made to the pamphlet whereupon 
the final electronic version was sent to Sydänlapset ja aikuiset ry. According to the feedback 
received the pamphlet was universally seen as useful, necessary and practical. 
Keywords 
Long QT Syndrome, community awareness, prevention of sudden cardiac death, pamphlet 
Miscellaneous 
The bachelor’s thesis is available in the library of JAMK University of Applied Sciences. 
Appendix: Pamphlet for Community Awareness of LQTS  
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1 LONG QT SYNDROME AND THESIS OBJECTIVES 
 
Long QT Syndrome (LQTS) is an inherited heart arrhythmia that is a cause of 
syncope and sudden cardiac death in young people. With proper treatment of 
LQTS, the risks of sudden death may be decreased. Those diagnosed with LQTS 
are affected physically through limitations caused by treatment and risk factors, 
and psychologically through uncertainty and anxiety that may be caused by the 
diagnosis. Consequently, individuals in close contact with persons diagnosed 
with LQTS have good reason to familiarize themselves with the effects that LQTS 
has on an individual in order to react appropriately to situations that may arise.  
 
During the Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation’s 
conference, Preventing Sudden Cardiac Death in the Young, September 20, 
2008, the Special Projects Director of the Canadian SADS Foundation, Blake 
Hurst expressed the importance of community education and awareness towards 
LQTS in the prevention of sudden cardiac death. It was from there that an idea 
for a bachelor’s thesis was created in the form of a pamphlet to be used as a tool 
for community awareness in Finland. During the initial planning phase of the 
thesis Sydänlapset ja -aikuiset ry was identified as a possible cooperating 
association.  
 
After discussing possible project possibilities with the contact person for 
Sydänlapset ja -aikuiset ry and taking her recommendations and concerns heard 
from parents of children with LQTS, the best course of action appeared to be in 
the form of a multifaceted information package that would be useful for all target 
groups.  
 
Improvement of public awareness of LQTS is promoted by providing a tool in the 
form of a pamphlet for distribution by Sydänlapset ja -aikuiset ry, Long QT 
branch. The target group for the pamphlet includes those in close cooperation 
with young people possibly suffering from LQTS. This group may include 
coaches, teachers, family members, and caregivers. Awareness of LQTS and 
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sudden arrhythmic death will increase among the target group with the 
assistance of the pamphlet. 
 
The thesis process included gathering information regarding LQTS from various 
sources such as research papers, various internet sites dedicated to LQTS which 
are supported by associations such as the SADS Foundation, practice guidelines 
and other various publications. Whereupon the information was compiled, the 
most important points regarding LQTS, raising awareness of LQTS and the 
criteria for an effective information package were filtered to establish a base for 
the theoretical portion of the thesis. Key words used in the search included: Long 
QT syndrome, sudden cardiac death, LQTS genes, and patient information 
pamphlet.  
 
A pamphlet format was chosen as an effective tool for information dissemination 
using the theoretical information gathered, as a shorter length assures that the 
reader is able to obtain essential information. In order to effectively evaluate the 
usefulness and clarity of the pamphlet, it was decided to present the pamphlet 
and information regarding its use to health professionals in Jyväskylä Central 
Hospital. Their feedback would be used in the further development of the 
pamphlet and the information presented, consequently resulting in the final 
pamphlet produced. 
 
In addition to the previously mentioned aims of the compilation of the thesis, 
additional goals include the authors’ professional development in health 
promotion, and acquiring knowledge regarding LQTS. Furthermore, the thesis 
process will facilitate the authors’ information gathering skills regarding health 
issues, which may be constructive in future professional endeavours. 
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2 LONG QT SYNDROME 
 
2.1. What is Long QT Syndrome? 
Long QT syndrome (LQTS) can be defined as a heart rhythm disorder that 
produces fast chaotic heartbeats which in turn may lead to fainting or in severe 
cases, sudden death. Long QT may occur as a result of genetic mutation, 
medical conditions such as congenital heart defects or certain medication. There 
are various treatments available such as the limitation of physical activity, 
avoidance of medications that may cause LQTS, prescribing medications that 
prevent arrhythmias and lastly implantable devices that control heart rhythm. 
(Mayo Foundation, 2008.) 
In further explanation, congenital LQTS is defined by the Levine et al. (2008, 591) 
as “an inherited disorder of cardiac repolarization that predisposes to syncope 
and to sudden death from polymorphic ventricular tachycardia.” Thus, in this 
examination, or rather, attempt to define LQTS whether it be congenital or 
acquired, it is clear that LQTS is a condition that affects the heart. More precisely, 
it affects the “electrical system” of the heart and interferes with the heart’s normal 
rhythm, which may then lead to fainting, seizures or sudden death. 
LQTS is a result of various ion channel gene mutations, of which three are most 
common: KCNQ1 mutation (LQT1), HERG mutation (LQT2), and SCN5A 
mutation (LQT3). Studies have shown that there are differences in responses and 
sensitivity to stimulation in the separate genotypes. As a result, triggers of cardiac 
events vary according to genotype. (Noda et.al. 2002, 975.)  Further reference to 
the triggers is made in conjunction with risk factors. In Finland, approximately one 
in 3 000 people are carriers of the gene (Toivonen et.al. 2008). 
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2.2. Symptoms of Long QT Syndrome 
 
Approximately 50% of individuals that suffer from LQTS do not experience 
symptoms or signs from their condition. Those with LQTS may become aware of 
their condition from the results of an electrocardiogram (ECG) which is performed 
for an unrelated reason. One additional form of diagnosis performed due to a 
family history of LQTS is genetic testing, the results of which identifies gene 
mutations as a confirmation or indication of LQTS. The most common symptoms 
and signs for those who suffer from LQTS include: fainting, seizures and sudden 
death. Although, as previously stated approximately half of the individuals that 
experience LQTS may not experience any signs or symptoms. (Mayo 
Foundation, 2008.) 
Fainting is the most common sign of LQTS. These fainting spells are also 
referred to as syncope and are caused by a temporary erratic heart beat. Fainting 
spells may occur when individuals with LQTS become excited, angry, scared or 
during exercise; in other words, during times of emotional or physical stress. 
Warning signs before a fainting spell are unusual for persons with LQTS. 
However, if signs of fainting are experienced before fainting; such as light-
headedness, heart palpitations, weakness and blurred vision, it is recommended 
that the individual sit or lie down and inform a person near to them. (Mayo 
Foundation, 2008.) 
Seizures occur due to the brain becoming increasingly deprived of oxygen as a 
result of the heart’s continuous erratic beating. According to the authors of 
mayoclinic.com some individuals with LQTS “have been misdiagnosed as having 
a seizure disorder and have even been treated with anti-epileptic medications.” 
Furthermore, according to the previously mentioned source most deaths related 
to LQTS occur in individuals aged between eleven and thirty years; it is also 
speculated that ten to fifteen percent of sudden infant death syndrome (SIDS) 
can be attributed to LQTS. Inherited LQTS symptoms may first occur during the 
first months of life or even as late as middle age. However, those individuals that 
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experience symptoms of LQTS normally experience their first symptoms before 
the age of forty. (Mayo Foundation, 2008.) 
Due to an increasing understanding of the genetic basis of LQTS it is possible to 
differentiate between different types of LQTS. For example LQT1 is triggered by 
exercise, LQT3 with inactivity, in other words, triggered by a low heart rate. LQT2 
may be triggered in the affected individual simply by being startled, for example 
an unexpected loud noise. (Levine et al. 2008, 591.)    
 
2.3. Causes of Long QT Syndrome 
 
LQTS occurs due to an electrical disturbance in the heart. The heart’s pumping 
actions are controlled by electrical impulses created in the sinus node. The sinus 
node is a group of cells contained in the upper right chamber of the heart. The 
impulses created in the sinus node cause the heart’s chambers to contract and 
relax; in other words, to beat. After every heart beat the sinus node in effect 
needs to “recharge” itself in preparation for the next heart beat; this process is 
referred to as repolarization. Thus, in LQTS the act of repolarization takes an 
extended amount of time. It is possible to monitor the heart’s electrical impulses 
with the aid of an electrocardiogram (ECG). The electrical impulses are displayed 
as waves of electrical activity and five distinct waves are identified in an ECG 
which are labeled P, Q, R, S and T. (See Figure 1.) When examining an ECG 
printout display waves labelled Q, R, S, T depict electrical activity in the lower 
chambers of the heart. The QT interval indicates the time the cells in the lower 
chambers of the heart require to discharge and recharge, thus, indicating the time 
at the heart’s disposal to contract and refill with blood prior to the next 
contraction. Therefore, it is possible to measure the QT interval and determine 
whether it is normal or not.  (Mayo Foundation, 2008.) 
7 
 
 
Figure 1. ECG intervals and waves (Yanowitz, 1997) 
As has been mentioned previously, “LQTS may occur as a result of genetic 
mutation, medical conditions such as congenital heart defects or certain 
medication.” According to Goldenberg et al. (2008, 2192) “The congenital LQTS 
is caused by mutations that encode cardiac ion channel proteins which regulate 
the flux of sodium, potassium, and calcium ions across myocellular membranes, 
resulting in prolonged ventricular repolarization and an increased risk for 
sustained ventricular tachyarrhythmias.” Therefore, congenital LQTS is a 
condition that exists before or at birth and is hereditary, in other words, occurring 
or tending to occur among family members. Goldenberg et al. further state that 
“These genetic disorders are associated with sudden cardiac death in young 
individuals without structural heart disease.” 
    
2.4. When To Seek Medical Advice 
Those at risk of LQTS include children, teenagers and young adults, including 
these persons’ family members who have experienced unexplained fainting 
8 
 
episodes, seizure episodes, near drowning or have a history of cardiac arrest. 
Furthermore, individuals related to persons known to have LQTS and individuals 
taking medication that is proved to be a cause of prolonged QT intervals are also 
at risk of LQTS. Lastly, individuals that suffer from eating disorders such as 
anorexia nervosa may also be at risk of LQTS due to low potassium, magnesium 
or calcium blood levels which are essential minerals for the functioning of the 
heart’s electrical system. (Mayo Foundation, 2008.) 
To reiterate the previously mentioned points, Levine et al. (2008, 599) state that 
“Congenital long QT syndrome should be suspected when the electrocardiogram 
shows the characteristic QT abnormalities when there is a history of syncope or 
ill-defined “seizures” in the patient or in the patient’s family.” Thus, by examining 
this information it is possible to deduce that individuals that experience any of the 
previously mentioned symptoms or meet any of the previously mentioned criteria 
should seek medical advice in order for the appropriate steps to be taken. 
 
2.5. Diagnosis and Treatment of Long QT Syndrome 
 
It is generally recommended that individuals see a medical professional if sudden 
fainting occurs during physical exertion, emotional stress or after the use of a 
new medication. Furthermore, since LQTS is a genetic disorder it is also 
recommended that individuals with close relatives whom have been diagnosed 
with LQTS also be tested. (Mayo Foundation, 2008.) 
Several test are available for confirming LQTS; these include an 
electrocardiogram (ECG), ambulatory ECG monitoring, event ECG monitoring, 
nonexercise stress test, electroencephalogram (EEG) and genetic testing. An 
EEG is performed to rule out any neurological causes of fainting such as a 
seizure disorder. (Mayo Foundation, 2008.) 
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Treatment of LQTS may involve surgery, the use of medical devices, medications 
or lifestyle changes. Treatment is undertaken with the goal of preventing 
arrhythmic heartbeat and sudden death. In the case of drug-induced LQTS 
treatment may simply involve the elimination of the drug in question; however 
additional treatment may be required. (Mayo Foundation, 2008.) 
Clinical management of Long QT Syndrome varies according to the response to 
treatment and risk stratification. Procedures that have been proven effective and 
have been generally accepted as beneficial for those diagnosed with LQTS 
include lifestyle modification, beta blocker treatment for those with a prolonged 
QT interval, and implantation of an implantable cardioverter-defibrillator (ICD) 
along with the use of beta blockers for patients with previous cardiac arrest who 
have reasonable expectation of survival with good functional status for more than 
one year. Treatment recommendations are explored in following discussion as 
according to the ACC/AHA/ESC Practice Guidelines-Executive Summary. (Zipes, 
Camm 2006, 1088.) 
Recommendations for treatment based on evidence or opinion that supports it’s 
usefulness include beta blocker treatment for those with a molecular LQTS 
analysis but a normal QT interval to prevent sudden cardiac death, and the 
implantation of an ICD combined with beta blocker treatment to reduce sudden 
cardiac death in LQTS patients experiencing syncope and/or VT despite beta 
blocker treatment. (Op. cit. p.1089.) 
Treatment that is less established by evidence or opinion as being effective 
includes left cardiac sympathetic neural denervation for LQTS patients with 
syncope, torsades de pointes, or cardiac arrest while receiving beta blockers, and 
implantation of an ICD with the use of beta blockers for prophylaxis of sudden 
cardiac death for patients in categories possibly associated with higher risk of 
cardiac arrest such as LQT2 and LQT3. (Op. cit. p. 1089.) 
Patients diagnosed with Long QT syndrome are recommended to make lifestyle 
changes to prevent cardiac events and avoid factors that may contribute to 
symptoms of LQTS. These factors vary according to the type of LQTS with which 
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the patient is diagnosed. Recommendations include avoidance of competitive 
sports activity for all types of LQTS. For LQT1, swimming should be limited or 
performed under supervision. LQT2 patients should avoid auditory stimuli 
especially during sleep which may include telephones and alarm clocks. All 
patients with LQTS should avoid drugs known to prolong the QT interval and 
those that deplete potassium/magnesium. (Op. cit. p. 1089.) 
Lifestyle changes may also include restrictions for sports and leisure activities.  
These restrictions should be discussed with a cardiologist to define the risks 
involved with LQTS, and the care being provided. It may be recommended to 
patients of LQTS to avoid forms of physical exercise in which a sudden loss of 
attention and functional ability may lead to accident or trauma. Sudden strenuous 
physical activity is prohibited for those with LQTS; however, endurance training 
and muscle strengthening improve the performance of the circulatory system and 
improve quality of life. (Käypä hoito, 2008.) 
Through genetic analysis, it is possible to identify all carriers of the gene mutation 
with a LQTS family. Identification of carriers allows treatment with a beta blocker 
prophylaxis against life-threatening arrhythmias for those identified as silent 
carriers. Additionally, genetic counseling may be provided to gene carriers to 
learn about the risk of transmitting the gene to offspring. (Zipes, Camm 2006, 
1089.)  
Recommendations for treatment of pediatric patients that have a high risk of 
sudden cardiac death and a genetic basis who have survived a cardiac arrest 
due to Long QT syndrome include ICD implantation when the patients are 
receiving optimal medical therapy. The benefit of the implantation must be 
considered, taking into account the risk of device malfunction, infection or lead 
failure. The role and benefit of ICD implantation for prevention of sudden cardiac 
death in young children has not been defined. However, in older children and 
adolescents, prophylactic ICD implantation may be considered based on data 
derived from clinical trials from adult patients suffering from Long QT syndrome.  
(Op. cit. p. 1093.) 
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Patients with an ICD device should receive regular follow-up and analysis of the 
status of the device. The ICD is programmed to achieve optimal sensitivity and 
specifity according to the nature of the underlying arrhythmia. Measures are 
taken to minimize the risk of inappropriate ICD treatment. The ICD in itself does 
not decrease the incidence of arrhythmias. However, it protects the patient from 
the consequences of the life-threatening arrhythmias characteristic of Long QT 
syndrome. (Op. cit. p. 1093-1094.) 
Treatment of Drug-Induced Long QT Syndrome includes the removal of the 
offending agent, management with intravenous magnesium sulfate, or potassium 
ion repletion for patients taking QT-prolonging drugs presenting few episodes of 
torsades de pointes and prolonged QT time. Atrial or ventricular pacing or 
isoproterenol is reasonable for patients taking QT-prolonging drugs who present 
with recurrent torsades de pointes. (Op. cit. p. 1094.)  
Patients diagnosed with Long QT syndrome have reason to avoid QT-prolonging 
drugs. (appendix 1.) These include some bronchodilators, anti-viral drugs, anti-
arrhythmic drugs, antidepressants, antihistamines and antibiotics, as well as 
others. (Toivonen et al. 2008.) 
 
3 LONG QT SYNDROME AND THE YOUNG 
 
 
3.1. Psychological Effects  
 
With the diagnosis of Long-QT syndrome comes the acknowledgement that the 
diagnosis includes a chance of sudden death in affected families. Advice may be 
given about the avoidance of strenuous exercise, mental stress, and loud noise 
to avoid trigger situations. According to studies of families going through 
screening for inherited cardiac arrhythmias, high levels of anxiety have been 
reported in parents of children at risk. (van Langen, Hofman, Tan, Wilde, 
2004,116.) According to a recent study regarding fears and anxiety with Long-QT 
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syndrome, conducted by Guiffre et al. (2008, 423), it is possible that children with 
Long-QT are not able to discuss feelings of anxiety and find difficulties in coping 
with anxiety. This, in some cases may result in behavioural symptoms.  
 
Results of a study regarding parental perceptions about congenital long QT 
syndrome revealed that parents did not report fear about their own death, but 
rather fear of their children dying. Parents alleviate their fear by making lifestyle 
changes, educating the community, and teaching children about their own health 
to enable them to make educated decisions. The study also revealed that parents 
experience frustration about the lack of knowledge regarding LQTS among health 
care professionals. (Farnsworth et al. 2006, 284.) 
   
Quality of life is affected with a diagnosis of Long QT. Families must make 
decisions to avoid situations that may trigger an event and are forced to make 
lifestyle decisions to avoid putting their children at risk. The family is forced to 
evaluate their attitudes toward life and make decisions about treatment options, 
possible maintenance issues and potential complications or side effects. In most 
cases, the decisions are made to protect the children, but not limit lifestyle. The 
timing of the diagnosis may also have a more significant impact on the life of an 
adolescent than a young child.  Adolescents are at a vulnerable stage in life, and 
the diagnosis may mean that career or other life goals may need to be re-
evaluated. These patients are at a risk for depression, and close observation and 
follow-up is crucial. (Op.cit. p. 288-289.) 
 
Parents are given the responsibility for deciding treatment and therapy options for 
children. These decisions may have a great impact on the life of the child. The 
study suggests that the uncertainty regarding treatment options and life with a 
potentially fatal disease does not seem to be an ongoing emotion. Parents adjust 
once they become more knowledgeable and a treatment plan is decided. (Op. cit. 
p.289.) 
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Parents of carrier children remain vulnerable to high levels of distress. Distress 
levels were high among parents who were highly distressed at previous 
assessments, were familiar with the disease for a longer time, had experienced a 
sudden death in the family, were lesser educated, and who were unsatisfied with 
the given information. Results of this study suggest that “most parents who have 
carrier children seem to experience difficulties adjusting to the new status of their 
children.” (Hendriks et al. 2005, 107,110.) 
 
If the diagnosis has been made after the death of a family member, the patients 
especially may feel guilt for the death of their loved one, and transmitting the 
gene mutation to one’s child may have an emotional impact on the parent.  
Patients and family members are encouraged to find information and support 
from various foundations aiming to provide support for those diagnosed with a 
genetic cardiac arrhythmia. (Levine et al. 2008, 598-599.) 
 
 
3.2. Effects of Treatment 
 
 
Long QT Syndrome, as mentioned earlier, is usually treated pharmacologically 
with beta-blockers, with the implantation of an internal cardioverter-defibrillator or 
pacemaker, or through surgical left cardiac sympathetic neural denervation.  
Treatment may have side-effects with which patients must learn to cope. 
Side effects of beta-blockers may include dyssomnia or sleep disturbances, 
nightmares, bradychardia, weakening of peripheral circulation, shortness of 
breath, muscle weakness and fatigue. During the beginning of treatment, the 
patient may experience dizziness when rising from a sitting or laying position.  
Beta-blockers may also disguise the symptoms of hypoglycaemia and strengthen 
symptoms of anaphylactic shock. Continual treatment of Long-QT with beta-
blockers is recommended throughout pregnancy and breastfeeding. Although 
beta-blockers are excreted in the breast-milk, the probability of adverse side 
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effects is low. Medication must be taken regularly, and must not be stopped 
suddenly. (Pharmaca Fennica, 2009)  
The implantation of an ICD does not usually put dramatic limits on the life of the 
patient.  Light exercise, a normal sexual life and travelling are not limited. 
However, swimming alone, combat sports and diving should be avoided. 
(Raatikainen, 2007.)  Although limitations are not drastic upon the implantation of 
an ICD, some consequences on the everyday life of the patient are observable. 
Patients may experience anxiety and depression, may feel a loss of control over 
life, and as a result may in some cases experience a lowered quality of life. 
Patients strive to gain control in their lives to reduce feelings of anxiety, 
depression and uncertainty. It is suggested that education and psychosocial 
support would be provided for patients following ICD implantation. (Flemme 2009, 
49.) 
 
4 RAISING AWARENESS OF LONG QT SYNDROME 
 
 
4.1. Risk Factors of Long QT Syndrome 
 
Data on specific risk factors for sudden cardiac death in children with LQTS is 
limited. Based on a study that utilized the International LQTS Registry to follow 
up on LQTS children to evaluate risk factors contributing to sudden cardiac death 
in children, male gender, QTc duration, and a history of prior syncope were 
identified as risk factors. The risks vary among patients, and are influenced by 
age, gender, genotype, environmental factors, therapy and possibly other 
modifier genes. The study concluded that careful follow-up is necessary for 
children with LQTS, as risk factors are time dependant and age specific.  
(Goldenberg et.al. 2008, 2185, 2190) 
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Arrhythmogenic syncope is often provoked by physical, emotional or auditory 
stimulation. According to a prospective longitudinal study of 328 families with 
Long QT Syndrome, 47% of probands (the first member of a family to be 
diagnosed with LQTS) had syncopal episodes in association with intense 
emotions, 41% with vigorous physical activity, 19% on awakening, 15% while 
swimming and 8% on arousal by auditory stimuli such as an alarm clock.  (Moss 
et al. 1991,1139). However, triggers of events vary according to the type of 
LQTS. Those with LQT1 are more likely to experience events triggered by 
exercise, while events are more likely to be triggered by emotion in those with 
LQT2. (Schwartz et al. 2001,91)  The variance in triggers for events may be seen 
in Figure 2. 
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Patients with a longer QTc and faster heart rates are at a greater risk of 
experiencing events compared to those with shorter QTc and slower heart rates.  
However, it is not determined how heart rate affects the risk of an event.   
 
It has been observed that there is an increased probability of cardiac events in 
women compared to men. However, although the inheritance of LQTS is 
autosomal dominant, it has been observed through a study conducted by 
Figure 2. Triggers for Cardiac Events in Long QT Syndrome 
(Schwartz et al. 2001.) 
16 
 
Imboden et al. (2006, 2744) that LQTS is more often transmitted to females. It 
has also been stated that women typically have longer QT intervals than men, 
and this difference increases at slower heart rates. The incidence of prolonged 
QT intervals and torsade de pointes is higher in women than men. (Zipes, Camm. 
2006, 1092) 
 
The influence of pregnancy on the risk for cardiac events in patients with 
hereditary Long QT syndrome has been investigated by Rashba et al. 
(1998,455), and it was determined that the postpartum period is associated with 
an increased risk for events for probands. First degree relatives may also be at 
risk, but not to the extent of probands. Rashba states that this increased risk may 
be related to cardiovascular changes that occur during pregnancy. Especially 
during the third trimester, heart rate increases. In Long QT patients, slower heart 
rates exaggerate the prolongation of the QT interval. After delivery, heart rate 
slows, and the QT interval increases. The psychological stress of caring for a 
newborn may also be related to the increase in cardiac events in the postpartum 
interval.  
 
It has been determined that age is a possible risk factor for sudden cardiac death, 
or life-threatening cardiac events among patients with Long QT syndrome. It has 
been suggested that patients with LQTS over the age of 40 have a lower risk of 
cardiac events than their younger counterparts. However, in a study conducted to 
investigate LQTS after the age of 40, Goldenberg et al. (2008, 2200) states that 
the risk remained for life-threatening cardiac events after the age of 40. 
 
Age has been proven to be a factor in risk stratification for cardiac events in 
patients with LQTS. Hobbs et al. (2006, 1249) concluded in a study conducted 
regarding LQTS and adolescence that males aged 10 to 12 years had four times 
a greater risk for cardiac events compared to females of the same age. However, 
there was no significant difference between the risks of females and males aged 
13-20 years. 
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The screening of athletes for cardiovascular diseases such as cardiomyopathies 
and ion channel abnormalities has been argued to prevent sudden cardiac death, 
and awareness campaigns have attempted to proclaim the importance of 
awareness of treatable genetic arrhythmias. Recommendations have been made 
by Zipes, Camm (2006, 1092) in the ACC/AHA/ESC Practice Guidelines for the 
gathering of preparticipation history and physical examination which includes a 
family history of premature or sudden cardiac death and evidence of 
cardiovascular diseases. As of yet, there is no protocol for athlete pre-
participation screening, however, it is recommended that all athletes that have 
experienced syncope should be evaluated to uncover cardiovascular disease or 
rhythm disorder, and cessation of competition is necessary for those suffering 
from serious symptoms.  The possibility and effectiveness of ECG-screening and 
echocardiography as preparticipation screening for heart disorders in athletes 
has been considered and researched. 
 
 
4.2. Strategies for Prevention of Sudden Cardiac Death 
 
Sudden cardiac death is defined by Viitasalo (2009) as a natural unexpected 
death that is a result of cardiac malfunction, in which the patient suddenly loses 
consciousness because of impaired circulation and dies within one hour after the 
beginning of symptoms. Sudden cardiac death is a result of a fatal arrhythmia or 
a structural defect of the heart caused by cardiac disease. 
 
The prognosis of survival of cardiac arrest drops dramatically if primary blood 
circulation is not restored within eight minutes. Viitasalo suggests that sudden 
cardiac death may be prevented by arranging that cardiopulmonary resuscitation 
would be accessible in all areas. The readiness of citizens to begin CPR must be 
developed. Family members of cardiac patients should especially master the 
skills of CPR. Automated external defibrillators for public use are widely available, 
and should be made available at public events and places. (Viitasalo, 2009) 
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Education on CPR is provided in Finland by the Finnish Red Cross.  They 
maintain clear instructions for resuscitation. See appendix 2 and appendix 3 for 
flow charts of resuscitation for adults and children as recommended by the 
Finnish Red Cross (2009). 
 
4.3. Community Education of Long QT Syndrome 
 
Long QT Syndrome affects the lives of many young people. If it is detected and 
treated early, sudden cardiac death may be prevented. Community education is 
important to increase awareness about cardiac arrhythmias and the warning 
signs involved with them. Warning signs should be monitored and those 
exhibiting signs should be referred to a cardiologist for assessment. Promotion of 
CPR training and the installation of Automated External Defibrillators in schools 
and sports facilities are effective at reducing the risk of cardiac death in all people 
experiencing cardiac arrest. (The Canadian SADS Foundation) 
 
Steps to educate the community about the recognition of warning signs of Long-
QT and the significance of Automated External Defibrillators in public buildings 
have been taken by Long QT or Sudden Arrhythmic Death foundations. Warning 
signs commonly include syncope during physical activity, syncope resulting from 
emotional distress or startle, and a family history of unexpected death of an 
otherwise healthy young person. (The Canadian SADS Foundation) 
 
Promotion of cardiopulmonary resuscitation training and promotion of Automated 
External Defibrillators would be beneficial especially for those in close 
cooperation with those diagnosed with Long QT Syndrome. Local CPR courses 
are available for education in these areas. The guidelines according to the Red 
Cross of Finland for cardiopulmonary resuscitation may be found in the appendix. 
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5 LONG QT SYNDROME PAMPHLET DEVELOPMENT 
 
5.1 Pamphlet Development for Community Education of Long QT Syndrome 
 
Using the theoretical information gathered, a pamphlet format was chosen as an 
effective tool for information dissemination. Shorter length assures that the reader 
is able to obtain essential information in a condensed form. According to Coulter 
et al (1998,16), during the making of a pamphlet matters that should be taken into 
account should include making the information accessible, acceptable, readable 
and comprehensible. In other words, the pamphlet should be made available to 
all those who may need the information and should contain reliable, accurate 
information in a simple, structured format. Coulter continues that the pamphlet 
should be attractive to the reader, and sufficiently cover the relevant topic with 
current information using understandable terminology. Also, the authors of the 
pamphlet should arrange for editorial review, make referral to evidence-based 
knowledge and sources, and include information on where to find further 
information about the subject. The credibility of the authors, publishers and 
sponsors also determine the reliability of the pamphlet. (Coulter et. al 1998,16.)   
 
Aldridge suggests (2004, 375) that to assure the readability of leaflet material, 
font size should be at least 12-point using bold or italics to emphasize key points. 
Text should be justified to the left margin and text should be divided using 
headings and subheadings. The use of bullets assists the reader in following the 
information and the overall appearance of the leaflet should be uncluttered. 
 
The guidelines for pamphlet development were adhered to as best as possible.  
As previously mentioned, the pamphlet should be attractive to the reader. Thus, a 
simple and structured layout was chosen. The colours were chosen to attract the 
eye of the reader without interfering with the information presented and three 
pictures were added to make the pamphlet aesthetically pleasing. Of these, one 
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picture depicting a grandmother with a grandchild was selected to represent the 
continuation of life and the genetic nature of LQTS. 
 
In order to effectively evaluate the usefulness and clarity of the pamphlet, it was 
decided to present the pamphlet and information regarding its use to health 
professionals in Jyväskylä Central Hospital. Their feedback would be used in the 
further development of the pamphlet and the information presented consequently, 
resulting in the final pamphlet produced. 
 
5.2. Presentation of the Pamphlet 
 
In order to effectively evaluate the pamphlet on LQTS for public education it was 
presented to nursing staff working in Jyväskylä Central Hospital: ward one 
(pediatric ward), and the pediatric cardiac outpatient clinic in which young 
patients with LQTS are provided care. The wards in question were chosen on the 
assumption that the staff in these wards would benefit from the information 
presented and evaluate the content of the pamphlet. 
 
The presentation was designed to provide the participants with general 
information concerning LQTS, and an overall view of the aim of the thesis and 
pamphlet. In an attempt to evaluate the usefulness and information contained in 
the pamphlet, a questionnaire (see Appendix 4, 5) was formulated for distribution 
amongst the nursing staff of the previously mentioned wards immediately after 
the presentation. According to Bork and Francis (1985, 907) “properly designed 
questionnaires can collect valid and reliable data for analyzing a research 
problem.”  
 
On the 27th of October 2009 the pamphlet was presented to nursing staff in 
Jyväskylä Central Hospital paediatric ward and the paediatric cardiac outpatient 
clinic. The ward was selected on the principle that the pamphlet is especially 
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aimed at reducing the risk of sudden cardiac death in the young.  The 
presentation consisted of a 14 slide Microsoft PowerPoint presentation lasting 
approximately 30 minutes, a 13 point questionnaire and a printed colour copy of 
the pamphlet. Six copies of the pamphlets were made available and distributed 
before the presentation in order for the nursing staff to have adequate time to 
examine the pamphlet. Fifteen nurses attended the presentation and all of those 
that attended answered the questionnaire (See appendices 4, 5).  
 
The presentation contained a brief explanation of LQTS, warning signs and 
symptoms of LQTS, diagnoses and treatment of LQTS, triggering factors of 
LQTS, possible psychological effects related to LQTS and its treatment, side 
effects of treatment, prevention of sudden cardiac death, pamphlet development 
and lastly the content of the pamphlet.  
 
5.3 Discussion and Evaluation of the Pamphlet 
 
Evaluation of the pamphlet was conducted with the assistance of a questionnaire 
containing questions to assist in the development and evaluation of the 
effectiveness and reliability of the pamphlet.  It contained questions regarding 
work experience, the nurse’s previous knowledge regarding LQTS, the need of 
the pamphlet produced, and the overall contents of the pamphlet concerning 
reliability, comprehensibility and format. 
 
Overall the feedback received was positive. Of the 15 participants two were 
students, one nurse had nil to three years work experience, six of the participants 
had four to nine years work experience and lastly, six of the participants had ten 
or more years work experience. Twelve of the thirteen points on the 
questionnaire were multiple choice questions with the last point available for the 
participants own comments and suggestions.  
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The feedback concerning the presentation made concerning LQTS and 
prevention of sudden cardiac death was overall unanimously positive. The 
majority of participants indicated that they were somewhat familiar with LQTS 
(ten participants) with a broad majority being aware of the risks associated with 
LQTS and agreeing that the information presented was beneficial. Three 
participants indicated that they had a basic knowledge level regarding LQTS, of 
which two participants were aware of the risks associated, and one participant 
somewhat aware of the risks. Lastly, two participants indicated that they had no 
knowledge at all regarding LQTS or the associated risks of sudden cardiac death.  
 
Feedback received concerning the pamphlet on LQTS revealed that the nurses 
deemed the topic of the pamphlet to be current, with over half of the nurses 
agreeing that the pamphlet responds to practical needs. However, seven of the 
participants felt that there should be more information regarding resuscitation; 
one of these participants commented especially that information should have 
been added regarding resuscitation in the case of no signs of life with another 
remarking that the resuscitation directions given in the pamphlet were too 
complicated. One of the participants also indicated that the language used in the 
pamphlet could have been simpler. 100 percent of participants found the 
information presented in the pamphlet to be reliable. All the suggestions were 
taken into consideration with the necessary changes made to the pamphlet. 
 
5.4 Conclusion 
 
Upon evaluation according to the criteria for a pamphlet of good quality, as 
discussed in chapter 5.1, the pamphlet met the majority of requirements 
concerning the layout and information content.  The pamphlet is widely 
accessible on the world-wide web, was deemed acceptable under review by 
partaking evaluators, and was written in a format to ensure the comprehensibility 
and fluency of the content.  The pamphlet contained current information from 
reliable sources and was supported by a foundation specializing in the subject. 
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To improve the reliability of the pamphlet, the contents were shown and 
evaluated by the paediatric cardiac outpatient clinic in the Jyväskylä Central 
Hospital, the contact person for Sydänlapset ja –aikuiset ry, and arrangements 
were made for doctoral approval of the contents.  As a result of insufficient time it 
was not possible to evaluate the effectiveness of the pamphlet upon publication 
and distribution among the target group. 
 
In conclusion, it is possible to evaluate the reliability of the pamphlet, but due to 
previously mentioned reasons, the effectiveness regarding the initial aims are not 
able to be assessed.  However, taking into consideration the lack of availability of 
similar material, one may assume that the pamphlet will be useful in raising 
awareness concerning Long QT Syndrome and sudden cardiac death. 
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APPENDICES 
Appendix 1. Drugs to be avoided by Congenital Long QT Syndrome patients  
(http://www.qtdrugs.org) 
 
  Generic Name Brand Name Class/Clinical Use 
 Albuterol Ventolin® Bronchodilator / Asthma 
 Albuterol Proventil® Bronchodilator / Asthma 
 Alfuzosin Uroxatral® Alpha1-blocker / Benign prostatic hyperplasia 
 Amantadine Symmetrel® Dopaminergic/Anti-viral / Anti-infective/ Parkinson's Disease 
 Amiodarone  Pacerone® Anti-arrhythmic / abnormal heart rhythm 
 Amiodarone  Cordarone® Anti-arrhythmic / abnormal heart rhythm 
 Amitriptyline Elavil® Tricyclic Antidepressant / depression 
 Amphetamine Dexedrine® CNS stimulant / ADHD 
 Amphetamine Adderall®  CNS stimulant / ADHD 
 Arsenic trioxide  Trisenox® Anti-cancer / Leukemia 
 Astemizole  Hismanal® Antihistamine / Allergic rhinitis 
 Atazanavir Reyataz®  Protease inhibitor / HIV 
 Atomoxetine Strattera® norepinephrine reuptake inhibitor / ADHD 
 Azithromycin Zithromax® Antibiotic / bacterial infection 
 Bepridil  Vascor® Anti-anginal / heart pain 
 Chloral hydrate Noctec® Sedative / sedation/ insomnia 
 Chloroquine Aralen® Anti-malarial / malaria infection 
 Chlorpromazine  Thorazine® Anti-psychotic/ Anti-emetic / schizophrenia/ nausea 
 Ciprofloxacin Cipro® Antibiotic / bacterial infection 
 Cisapride Propulsid® GI stimulant / heartburn 
 Citalopram Celexa® Anti-depressant / depression 
 Clarithromycin Biaxin® Antibiotic / bacterial infection 
 Clomipramine Anafranil® Tricyclic Antidepressant / depression 
 Clozapine Clozaril® Anti-psychotic / schizophrenia 
 Cocaine Cocaine Local anesthetic /  
 Desipramine Pertofrane® Tricyclic Antidepressant / depression 
 Dexmethylphenidate Focalin® CNS stimulant / ADHD 
 Diphenhydramine Benadryl® Antihistamine / Allergic rhinitis, insomnia 
 Diphenhydramine Nytol® Antihistamine / Allergic rhinitis, insomnia 
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 Disopyramide  Norpace® Anti-arrhythmic / abnormal heart rhythm 
 Dobutamine Dobutrex® Catecholamine / heart failure and shock 
 Dofetilide  Tikosyn® Anti-arrhythmic / abnormal heart rhythm 
 Dolasetron Anzemet® Anti-nausea / nausea, vomiting 
 Domperidone Motilium® Anti-nausea / nausea 
 Dopamine Intropine® Inotropic agent / heart failure; hypotension; shock 
 Doxepin Sinequan® Tricyclic Antidepressant / depression 
 Droperidol  Inapsine® Sedative;Anti-nausea / anesthesia adjunct, nausea 
 Ephedrine Broncholate® Bronchodilator, decongestant / Allergies, sinusitis, asthma 
 Ephedrine Rynatuss® Bronchodilator, decongestant / Allergies, sinusitis, asthma 
 Epinephrine Bronkaid® catecholamine, vasoconstrictor / anaphylaxis, allergic reactions 
 Epinephrine Primatene® catecholamine, vasoconstrictor / anaphylaxis, allergic reactions 
 Erythromycin  Erythrocin® Antibiotic;GI stimulant / bacterial infection; increase GI motility 
 Erythromycin  E.E.S.®  Antibiotic;GI stimulant / bacterial infection; increase GI motility 
 Felbamate  Felbatrol® Anti-convulsant / seizure 
 Fenfluramine Pondimin® Appetite suppressant / dieting, weight loss 
 Flecainide Tambocor® Anti-arrhythmic / abnormal heart rhythm 
 Fluconazole Diflucan® Anti-fungal / fungal infection 
 Fluoxetine  Prozac® Anti-depressant / depression 
 Fluoxetine  Sarafem® Anti-depressant / depression 
 Foscarnet  Foscavir® Anti-viral / HIV infection 
 Fosphenytoin Cerebyx® Anti-convulsant / seizure 
 Galantamine Reminyl® Cholinesterase inhibitor / Dementia, Alzheimer's 
 Gatifloxacin Tequin® Antibiotic / bacterial infection 
 Gemifloxacin Factive® Antibiotic / bacterial infection 
 Granisetron Kytril® Anti-nausea / nausea and vomiting 
 Halofantrine  Halfan® Anti-malarial / malaria infection 
 Haloperidol  Haldol® Anti-psychotic / schizophrenia, agitation 
 Ibutilide Corvert® Anti-arrhythmic / abnormal heart rhythm 
 Imipramine Norfranil® Tricyclic Antidepressant / depression 
 Indapamide Lozol® Diuretic / stimulate urine & salt loss 
 Isoproterenol Medihaler-Iso® Catecholamine / allergic reaction 
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 Isoproterenol Isupres® Catecholamine / allergic reaction 
 Isradipine Dynacirc® Anti-hypertensive / high blood pressure 
 Itraconazole Sporanox® Anti-fungal / fungal infection 
 Ketoconazole Nizoral® Anti-fungal / fungal infection 
 Lapatinib Tykerb® Anti-cancer / breast cancer, metastatic 
 Lapatinib Tyverb® Anti-cancer / breast cancer, metastatic 
 Levalbuterol Xopenex®  Bronchodilator / asthma 
 Levofloxacin Levaquin® Antibiotic / bacterial infection 
 Levomethadyl Orlaam® Opiate agonist / pain control, narcotic dependence 
 Lisdexamfetamine Vyvanse®  CNS stimulant / ADHD 
 Lithium Lithobid® Anti-mania / bipolar disorder 
 Lithium Eskalith® Anti-mania / bipolar disorder 
 Mesoridazine Serentil® Anti-psychotic / schizophrenia 
 Metaproterenol Metaprel® Bronchodilator / asthma 
 Metaproterenol Alupent® Bronchodilator / asthma 
 Methadone Methadose® Opiate agonist / pain control, narcotic dependence 
 Methadone Dolophine® Opiate agonist / pain control, narcotic dependence 
 Methylphenidate Ritalin® CNS stimulant / ADHD 
 Methylphenidate Concerta®  CNS stimulant / ADHD 
 Mexiletine Mexitil® Anti-arrhythmic / Abnormal heart rhythm 
 Midodrine ProAmatine® Vasoconstrictor / low blood pressure, fainting 
 Moexipril/HCTZ  Uniretic® Anti-hypertensive / high blood pressure 
 Moxifloxacin  Avelox® Antibiotic / bacterial infection 
 Nicardipine  Cardene® Anti-hypertensive / high blood pressure 
 Nilotinib Tasigna®  Anti-cancer / Leukemia 
 Norepinephrine Levophed® Vasconstrictor, Inotrope / shock, low blood pressure 
 Nortriptyline Pamelor® Tricyclic Antidepressant / depression 
 Octreotide  Sandostatin® Endocrine / acromegaly, carcinoid diarrhea 
 Ofloxacin Floxin® Antibiotic / bacterial infection 
 Ondansetron Zofran® Anti-emetic / nausea and vomiting 
 Oxytocin Pitocin® Oxytocic / Labor stimulation 
 Paliperidone Invega® Antipsychotic, atypical / Schizophrenia 
 Paroxetine Paxil® Anti-depressant / depression 
 Pentamidine  NebuPent® Anti-infective / pneumocystis pneumonia 
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 Pentamidine  Pentam® Anti-infective / pneumocystis pneumonia 
 Perflutren lipid microspheres Definity®  
Imaging contrast agent / 
Echocardiography 
 Phentermine Fastin® Appetite suppressant / dieting, weight loss 
 Phentermine Adipex® Appetite suppressant / dieting, weight loss 
 Phenylephrine Neosynephrine® 
Vasoconstrictor, decongestant / low 
blood pressure, allergies, sinusitis, 
asthma 
 Phenylpropanolamine Dexatrim® Decongestant / allergies, sinusitis, asthma 
 Phenylpropanolamine Acutrim® Decongestant / allergies, sinusitis, asthma 
 Pimozide Orap®  Anti-psychotic / Tourette's tics 
 Probucol Lorelco® Antilipemic / Hypercholesterolemia 
 Procainamide  Pronestyl® Anti-arrhythmic / abnormal heart rhythm 
 Procainamide  Procan®  Anti-arrhythmic / abnormal heart rhythm 
 Protriptyline Vivactil® Tricyclic Antidepressant / depression 
 Pseudoephedrine PediaCare® Decongestant / allergies, sinusitis, asthma 
 Pseudoephedrine Sudafed® Decongestant / allergies, sinusitis, asthma 
 Quetiapine  Seroquel®  Anti-psychotic / schizophrenia 
 Quinidine Quinaglute® Anti-arrhythmic / abnormal heart rhythm 
 Quinidine Cardioquin®  Anti-arrhythmic / abnormal heart rhythm 
 Ranolazine Ranexa®  Anti-anginal / chronic angina 
 Risperidone  Risperdal®  Anti-psychotic / schizophrenia 
 Ritodrine Yutopar® Uterine relaxant / prevent premature labor 
 Roxithromycin* Rulide® Antibiotic / bacterial infection 
 Salmeterol  Serevent®  Sympathomimetic / asthma, COPD 
 Sertindole Serdolect® Antipsychotic, atypical / Anxiety, Schizophrenia 
 Sertindole Serlect® Antipsychotic, atypical / Anxiety, Schizophrenia 
 Sertraline Zoloft® Anti-depressant / depression 
 Sibutramine Meridia® Appetitie suppressant / dieting, weight loss 
 Solifenacin VESIcare® muscarinic receptor anatagonist / treatment of overactive bladder 
 Sotalol  Betapace®  Anti-arrhythmic / abnormal heart rhythm 
 Sparfloxacin  Zagam®  Antibiotic / bacterial infection 
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 Sunitinib Sutent® Anti-cancer / RCC, GIST 
 Tacrolimus  Prograf® Immunosuppressant / Immune suppression 
 Tamoxifen  Nolvadex®  Anti-cancer / breast cancer 
 Telithromycin Ketek® Antibiotic / bacterial infection 
 Terbutaline Brethine® Bronchodilator / asthma 
 Terfenadine Seldane® Antihistamine / Allergic rhinitis 
 Thioridazine Mellaril®  Anti-psychotic / schizophrenia 
 Tizanidine  Zanaflex®  Muscle relaxant /  
 Tolterodine Detrol® Bladder Antispasmodic /  
 Tolterodine Detrol LA® Bladder Antispasmodic /  
 Trimethoprim-Sulfa Bactrim® Antibiotic / bacterial infection 
 Trimethoprim-Sulfa Sulfa® Antibiotic / bacterial infection 
 Trimipramine Surmontil® Tricyclic Antidepressant / depression 
 Vardenafil Levitra®  phosphodiesterase inhibitor / vasodilator 
 Venlafaxine  Effexor®  Anti-depressant / depression 
 Voriconazole VFend®  Anti-fungal / anti-fungal 
 Ziprasidone Geodon®  Anti-psychotic / schizophrenia 
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Appendix 2:  Cardiopulmonary resuscitation for children under 8 years (Finnish 
Red Cross, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the child conscious? 
NO 
Start CPR. 
30 chest compressions. 
Does the breathing return 
to normal? 
NO                      YES 
Open the airways. Is the 
child breathing normally? 
If there is more than 
one person to help: Call 
112 immediately 
NO                   YES 
5 rescue breaths 
2 rescue breaths 
Continue CPR with the 
compression:breath ratio 
of 30:2 
Continue until professional help 
arrives, the patient resumes 
breathing or you do not have the 
strength to continue 
Put the patient in the 
recovery position.  Monitor 
the breathing until 
professional help arrives. 
If you’re alone: Repeat the 
sequence 30:2 once 
before you call 112. 
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Appendix 3. Cardiopulmonary resuscitation for adults (Finnish Red Cross, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the person conscious? 
NO 
Call 112 
Open the airways. Is the person 
breathing normally? 
YES 
NO 
Begin cardiovascular 
resuscitation. 
30 chest compressions 
Begin pulmonary resuscitation.   
2 rescue breaths. 
Continue CPR with the 
compression:breath ratio of 30:2 
Continue until professional help arrives, the 
patient resumes breathing or you do not 
have the strength to continue 
Put the patient in the recovery position.  
Monitor the breathing until professional 
help arrives. 
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Appendix 4. Questionnaire for Pamphlet Development 
Long QT Syndrome: A Pamphlet for Community Awareness in Prevention 
of Sudden Cardiac Death in the Young, Bachelor’s Thesis 
Pierre Lettenga, Helena Lustig 
 
Please help us to further develop our bachelor’s thesis and pamphlet by 
answering the following questions. 
 
Personal Information 
 
1. What ward do you work in?     ___________________________________ 
 
2. How many years of nursing experience do you have? 
 
a.) 0-3 years 
b.) 4-9 years 
c.) 10 or more years 
 
Feedback on Presentation in the Ward on Long QT Syndrome 
 
3. Was Long QT Syndrome familiar to you before the presentation? 
 
a.) not familiar at all 
b.) somewhat familiar 
c.) I have had the basic information concerning Long QT Syndrome 
d.) I have considered myself an expert on Long QT Syndrome 
 
4. Have you been aware of the risks (namely sudden cardiac death in young) 
connected to Long QT Syndrome and the value of community awareness 
regarding it? 
 
a.) this information was new to me 
b.) I have been somewhat aware of these issues 
c.) I have been aware of these issues 
d.) I have been aware of these issues and have worked in their development 
 
5. Was the information presented useful? 
 
a.) I did not find the information at all useful 
b.) somewhat useful 
c.) yes 
d.) I find it difficult to determine the usefulness 
 
Feedback on Pamphlet for Long QT Syndrome 
 
6. How would you evaluate the need for the pamphlet presented? 
 
a.) there is enough information on the topic available to all sectors 
b.) information is still needed and the topic is timely and useful 
c.) information is still needed and the pamphlet responds to practical needs 
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d.) I am unable to evaluate the need of the pamphlet 
 
7. In your opinion, is the length of the pamphlet suitable? 
 
a.) the pamphlet contains the right amount of information in the right amount of 
space 
b.) the pamphlet should include more information 
c.) information in the pamphlet should be more concise. 
 
8. Evaluation of the contents of the pamphlet: 
 
a.) the pamphlet contains all the essential information 
b.) the pamphlet should contain information on: __________________________ 
______________________________________________________________ 
 
9. Is the route of distribution planned for the pamphlet effective in your opinion, in 
that those who may benefit from it will be able to access it? 
 
a.) yes 
b.) no  
why not?_______________________________________________ 
______________________________________________________ 
 
10. Is the information provided in the pamphlet, in your opinion, reliable? 
 
a.) yes 
b.) no 
why not? ______________________________________________ 
______________________________________________________ 
 
11. Is there any way that the information could be made more reliable? 
 
a.) yes  
how? _________________________________________________ 
______________________________________________________ 
b.) no 
 
12. Is the information provided in the pamphlet written in a way that is 
understandable for the target group (members of the community)? 
 
a.) The information is readable and understandable 
b.) Some improvements may be made to make the information easier to read 
and understandable for the target group, namely: 
_____________________________________________________ 
_____________________________________________________ 
_____________________________________________________ 
 
13. Please give suggestions for improvements for the pamphlet or other 
comments/suggestions: 
_____________________________________________________________
_____________________________________________________________
____________________________________________________________ 
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Appendix 5. Questionnaire for Pamphlet Development (Finnish) 
Pitkä QT -oireyhtymä –esite: Yleisen tietoisuuden lisääminen nuorten 
sydänperäisten äkkikuolemien ehkäisemiseksi 
opinnäytetyö 
Pierre Lettenga, Helena Lustig 
 
Pyydämme ystävällisesti sinua auttamaan meitä opinnäytetyömme ja esitteen 
kehittämisessä vastaamalla seuraaviin kysymyksiin.  
 
Esitiedot  
 
14. Millä osastolla työskentelet?     _____________________________________ 
 
15. Kuinka monta vuotta olet työskennellyt hoitotyössä?   
  
d.) 0-3 vuotta 
e.) 4-9 vuotta 
f.) 10 tai enemmän 
 
Palaute Pitkä QT -oireyhtymä –esityksestä  
 
16. Oliko Pitkä QT -oireyhtymä sinulle tuttu ennen esitystä? 
 
e.) ei lainkaan tuttu 
f.) tiesin joitakin yksittäisiä asioita sairaudesta 
g.) halitsin perustiedot 
h.) olin perehtynyt tarkasti sairauteen 
 
17. Oletko ollut tietoinen Pitkä QT -oireyhtymän riskeistä (erityisesti sydänperäiset 
äkkikuolemat nuorilla) ja riskeihin liittyvän yleisen tietoisuuden merkityksestä?  
 
e.) tämä tieto oli uutta minulle 
f.) olen ollut osittain tietoinen asiasta 
g.) olen ollut tietoinen asiasta  
h.) olen ollut tietoinen asiasta ja työskennellyt tietoisuuden lisäämisen 
kehittämiseksi 
 
18. Oliko esitetty tieto hyödyllistä? 
 
e.) ei lainkaan 
f.) osittain hyödyllistä 
g.) kyllä  
h.) en osaa sanoa 
 
 
Palaute Pitkä QT -oireyhtymä –esitteestä 
 
19. Kuinka arvioisit esitteen tarpeellisuutta? 
 
e.) tietoa on ollut aikaisemmin riittävästi saatavilla kaikille sitä tarvitseville 
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f.) tietoa tarvitaan edelleen ja aihe on ajankohtainen 
g.) tietoa tarvitaan edelleen ja esite vastaa käytännön tarpeita  
h.) en osaa sanoa 
 
20. Onko tiedon määrä sopiva suhteessa esitteen pituuteen? 
 
a.) tietoa on riittävästi ja pituus on sopiva 
b.) esite kaipaa lisää tietoa 
c.) esitettä tulisi tiivistää 
 
21. Esitteen sisällön arviointi 
 
a.) esitteessä on kaikki oleelliset asiat 
b.) esitteestä puuttuu oleellista tietoa, mitä ______________________________ 
______________________________________________________________ 
 
22. Onko esitteen jakelu suunniteltu mielestäsi siten, että kaikki tietoa tarvitsevat 
saavat sen helposti? 
 
c.) kyllä 
d.) ei, miksi? 
______________________________________________________________
______________________________________________________________ 
 
23. Onko tieto esitteessä mielestäsi luotettavaa? 
 
c.) kyllä   
d.) ei, miksi?  
______________________________________________________________
______________________________________________________________ 
 
24. Voisiko esitteen luotettavuutta jollakin keinolla lisätä? 
 
c.) kyllä, miten? 
______________________________________________________________
______________________________________________________________ 
d.) ei 
 
25. Onko esite kirjoitettu ymmärrettävästi kohderyhmä huomioiden? 
 
c.) Sisältö on luettavaa ja ymmärrettävää 
d.) Osan tekstistä voisi muokata siten, että kohderyhmän olisi sitä helpompi 
lukea ja ymmärtää. Kerro tarkemmin:  
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
 
26. Muita kommentteja ja ehdotuksia: 
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________ 
Long QT Syndrome
What is Long QT Syndrome (LQTS)?
LQTS is an inherited heart rhythm disorder in •	
which the ion channels in the heart muscle 
cells do not function properly.
The heart muscles take longer than normal to •	
recharge between beats; this may cause heart 
arrhythmias in which the heartrate increases 
to a point where the heart is not able to pump 
blood to the brain.  
This causes syncope and in severe cases  ̀
ventricular fibrillation that causes cardiac 
arrest and sudden death.
    
First symptoms usually occur during childhood •	
or young adulthood.
Syncope may resemble fainting or epileptic •	
seizure.
My child’s treatment includes:
medication _____________, ___times per  ђ
day
cardioverter-defibrillator/pacemaker ђ
other information concerning my child´s care:  ђ
__________________________________
____________
My child’s symptoms have included:
fainting ђ
dizziness ђ
has not experienced symptoms ђ
other: _____________________________ ђ
__________________________________
Triggers of events have included:
physical activity ђ
sleep ђ
startle/loud noises ђ
emotional stress ђ
other: _____________________________ ђ
__________________________________
__________________________________
Other information: _______________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
In case of symptoms or in an emergency 
please contact: _______________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
More information may be found:
Sydänlapset ja -aikuiset ry:
www.sydanlapsetja-aikuiset.fi
Suomen Punainen Risti
www.redcross.fi
Suomen Sydänliitto ry
www.sydanliitto.fi
Compiled by: 
Bauke Pier Lettenga
Helena Lustig
In cooperation with:
Sydänlapset ja -aikuiset ry, Pitkä QT-jaosto
Jyväskylän Ammattikorkeakoulu
First aid
1. Clarify whether the person is conscious. 
2. Clear and secure the airways: Lift the chin 
upwards with two fingers of one hand and bend 
the head back with the other hand by pressing on 
the forehead. Check to see if the chest is moving, 
whether you can hear normal breathing sounds or 
whether you can feel the person breathing on your 
cheek.   
3. If the person does not awaken or react to sti-
mulation, get help and call the emergency number 
112. Follow the directions given.
4. If the person has a definite diagnosis of Long QT 
Syndrome, strike the person in the sternum with 
your fist. This may cause the heart rhythm to return 
to normal.
5. If breathing is normal, turn the person into re-
covery position on their side to secure their breat-
hing. Observe the condition of the person carefully 
until professional help arrives.  
6. Make sure the head is in a position in which the 
airways are open. Monitor breathing and cons-
ciousness level until professional help arrives.
Good to know
Symptoms (and syncope) usually occur with little •	
or no warning.
Diagnosis and treatment may be followed by •	
anxiety, depression and may cause behavioural 
symptoms.
Medication may cause: fatigue, lowered blood •	
pressure, blood sugar fluctuation.
Preventive Action:
Sudden cardiac death may be prevented through •	
CPR (cardiopulmonary resuscitation). Contact the 
local Red Cross for First-Aid course information.
Automated external defibrillators should be made •	
available at public events and places.
Warning signs
    
Dizziness, weakness, paleness, clammy skin, •	
nausea, or lack of consciousness
during physical exertion ̀
during emotional stress ̀
while nervous or when startled  ̀
Family history of sudden deaths or syncope.•	
Family history of unexplained accidents/deaths •	
especially while swimming.
Treatment
Avoidance of risk factors, for example physical •	
overexertion, swimming, crapulence, fasting, 
fluid and salt unbalance, startles, certain medi-
cations.
Betablocker medication.•	
Implantable cardioverter-defibrillator.•	
Pitkä QT-oireyhtymä
Mikä pitkä QT-oireyhtymä on?
Sydämen rytmihäiriösairaus, jossa sydänlihas-•	
solujen ionikanavat eivät toimi normaalisti.
Sydämen palautumisaika lyönnin jälkeen  ̀
pitenee.
Yleensä perinnöllinen.•	
Saattaa aiheuttaa rytmihäiriökohtauksia, jossa •	
syke muuttuu niin nopeaksi, että sydän ei pys-
ty pumppaamaan verta aivoihin riittävästi.
Tämä aiheuttaa tajunnan menetyksen,  ̀
joka voi muistuttaa ohimenevää pyörtymistä 
tai epileptistä kohtausta.
Pahimmillaan rytmihäiriö voi aiheuttaa  ̀
kammiovärinän ja johtaa sydämen pysähtymi-
seen.
Ensimmäiset oireet esiintyvät yleensä lapsilla •	
tai nuorilla aikuisilla.
Lapseni hoitoon kuuluu:
lääkitys _____________, ___kertaa päivässä ђ
tahdistin ђ
muuta hoitoon liittyvää tietoa: ____________ ђ
__________________________________
Lapsellani on esiintynyt seuraavia oireita:
huimaus ђ
tajunnan menetys ђ
ei ole esiintynyt oireita ђ
muuta: _____________________________ ђ
__________________________________
Oireet ovat esiintyneet seuraavissa 
tilanteissa:
fyysinen rasitus ђ
nukkuminen ђ
jännittäminen, pelästyminen, kovat äänet ђ
henkinen rasitus ђ
muuta: _____________________________ ђ
__________________________________
Lisätietoa: _____________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
Oireiden ilmaantuessa ja hätätilanteissa 
ota yhteyttä: __________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
Lisää tietoa saat:
Sydänlapset ja -aikuiset ry:
www.sydanlapsetja-aikuiset.fi
Suomen Punainen Risti
www.redcross.fi
Suomen Sydänliitto ry
www.sydanliitto.fi
Esitteen ovat koonneet: 
Bauke Pier Lettenga
Helena Lustig
Yhteistyössä:
Sydänlapset ja -aikuiset ry, Pitkä QT-jaosto
Jyväskylän Ammattikorkeakoulu
Tajunnan menettäneen ensiapu
Selvitä, onko hän herätettävissä puhuttelemalla 1. 
ja ravistelemalla.
Avaa hengitystiet ja tarkista hengitys: kohota 2. 
toisen käden kahdella sormella leuan kärkeä 
ylöspäin ja taivuta päätä taaksepäin toisella 
kädellä otsaa painaen. Katso, liikkuuko rinta-
kehä, kuuluuko normaali hengityksen ääni tai 
tuntuuko poskellasi ilman virtaus.  
Jos henkilö ei hengitä, eikä reagoi käsittelyyn, 3. 
hae apua, ja soita hätäkeskukseen 112. Nou-
data hätäkeskuksen ohjeita.
Jos henkilö sairastaa epäilyksettä pitkä QT-4. 
oireyhtymää, lyö henkilöä nyrkillä rintalastaan. 
Nyrkiniskulla sydän saatetaan saada tahdis-
tettua normaaliin rytmiin. Aloita tarvittaessa 
painelu-puhalluselvytys.
Jos hengitys on normaalia, käännä henkilö kyl-5. 
kiasentoon hengityksen turvaamiseksi. Seuraa 
hänen tilaansa kunnes ammattihenkilö ottaa 
vastuun.  
Varmista pään asento niin, että hengitystiet py-6. 
syvät auki. Tarkkaile hengitystä ja mahdollista 
heräämistä muun avun saapumiseen asti.
Hyvä tietää
Tajunnan menetykset ilmenevät yleensä äkilli-•	
sesti ilman ennakkovaroituksia.
Oireyhtymän toteamisen seurauksena voi esiin-•	
tyä ahdistusta, masennusta ja käyttäytymisvai-
keuksia.
Lääkitys voi aiheuttaa väsymystä, alhaisen •	
verenpaineen tai verensokerin vaihteluja.
Ennakoivat toimenpiteet:
Sydänperäisiä äkkikuolemia voi ehkäistä paine-•	
luelvytyksellä. Ota yhteyttä Suomen Punaiseen 
Ristiin saadaksesi tietoa ensiapukursseista.
Sähköisiä defibrillaattoreita (sydämen rytminsiir-•	
tolaitteita) tulisi olla saatavilla julkisissa tapahtu-
missa ja paikoissa.
Varoittavat oireet ja merkit
    
Huimaus, heikkouden tunne, kalpeus, kylmä •	
hiki, pahoinvointi tai tajunnan menetys
fyysisen rasituksen aikana ̀
henkisen rasituksen aikana ̀
jännittäessä tai pelästymisen seurauksena ̀
Suvussa esiintynyt äkkikuolemia tai tajunnan •	
menetystä.
Suvussa esiintynyt selittämättömiä onnetto-•	
muuksia erityisesti uimatilanteissa.
Hoitokeinot
Riskitilanteiden välttäminen, esim. liian voima-•	
kas fyysinen rasitus, uinti, krapula, paasto tai 
neste-ja suolatasapainon järkkyminen, pelästy-
minen, tietyt lääkkeet.
Beetasalpaajalääkitys.•	
Rytmihäiriötahdistin.•	
